Literature DB >> 649945

Commercial factor VIII associated hepatitis, 1974-75, in the United Kingdom: a retrospective survey.

J Craske, P Kirk, B Cohen, E M Vandervelde.   

Abstract

A retrospective survey of transfusion hepatitis associated with a brand of commercial Factor VIII was carried out in 24 Haemophilia Centres from January 1974 until December 1975. Of 371 patients who were transfused with this product, and were followed up, 78 cases of hepatitis affecting 66 patients were found (17.7%). Two types of hepatitis were observed: hepatitis B and non-B hepatitis, the latter with an incubation period of between 8 and 60 days. Twelve patients contracted two types of hepatitis, non-B followed by hepatitis B. Only one patient died after contracting hepatitis B. Four of the suspect batches of concentrate were found to be positive for HBsAg by radioimmunoassay. There was evidence that the presence of hepatitis B surface antibody in a patient's serum prior to exposure was associated with immunity to hepatitis B. Evidence was presented suggesting that the non-B hepatitis observed was not due to hepatitis A. The factors affecting the incidence of transfusion hepatitis in haemophiliacs were discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 649945      PMCID: PMC2129808          DOI: 10.1017/s0022172400024773

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  10 in total

1.  Transfusion-associated hepatitis not due to viral hepatitis type A or B.

Authors:  S M Feinstone; A Z Kapikian; R H Purcell; H J Alter; P V Holland
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

2.  Antibody responses in viral hepatitis, type B.

Authors:  L F Barker; M R Peterson; N R Shulman; R Murray
Journal:  JAMA       Date:  1973-02-26       Impact factor: 56.272

3.  Clinical evaluation of the turkey-erythrocyte passive-haemagglutination test for hepatitis-B surface antigen.

Authors:  I L Chrystie; M N Islam; J E Banatvala
Journal:  Lancet       Date:  1974-06-15       Impact factor: 79.321

4.  Hepatitis-B antigen in saliva and semen.

Authors:  J Heathcote; C H Cameron; D S Dane
Journal:  Lancet       Date:  1974-01-19       Impact factor: 79.321

5.  Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom.

Authors:  R Biggs
Journal:  Br J Haematol       Date:  1974-03       Impact factor: 6.998

6.  Hepatitis and clotting-factor concentrates.

Authors:  C K Kasper; S A Kipnis
Journal:  JAMA       Date:  1972-07-31       Impact factor: 56.272

7.  An outbreak of hepatitis associated with intravenous injection of factor-VIII concentrate.

Authors:  J Craske; N Dilling; D Stern
Journal:  Lancet       Date:  1975-08-02       Impact factor: 79.321

8.  Hemagglutination assay for antigen and antibody associated with viral hepatitis.

Authors:  G N Vyas; N R Shulman
Journal:  Science       Date:  1970-10-16       Impact factor: 47.728

9.  Some considerations regarding active immunization with HBsAg.

Authors:  A M Prince; N Hashimoto; A R Neurath; C Trepo
Journal:  Dev Biol Stand       Date:  1975

10.  Mutliple hepatitis viruses in multiple attacks of acute viral hepatitis.

Authors:  J W Mosley; A G Redeker; S M Feinstone; R H Purcell
Journal:  N Engl J Med       Date:  1977-01-13       Impact factor: 91.245

  10 in total
  7 in total

Review 1.  Non-A, non-B hepatitis: dead ends or new horizons?

Authors:  S A Iwarson
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-17

Review 2.  Priorities for immunisation against hepatitis B.

Authors:  A J Zuckerman
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-06

3.  Viral exposure and abnormal liver function in haemophilia.

Authors:  B A McVerry; M G Ross; W A Knowles; J Voke
Journal:  J Clin Pathol       Date:  1979-04       Impact factor: 3.411

4.  Cross-border paid plasma donation among injection drug users in two Mexico-U.S. border cities.

Authors:  Patricia Volkow; Kimberly C Brouwer; Oralia Loza; Rebeca Ramos; Remedios Lozada; Richard S Garfein; Carlos Magis-Rodriguez; Michelle Firestone-Cruz; Steffanie A Strathdee
Journal:  Int J Drug Policy       Date:  2009-02-20

5.  Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients.

Authors:  M L Fletcher; J M Trowell; J Craske; K Pavier; C R Rizza
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-10

6.  Lymphocyte subset ratios and factor VIII usage in haemophilia.

Authors:  A C Beddall; K Al-Rubei; M D Williams; F G Hill
Journal:  Arch Dis Child       Date:  1985-06       Impact factor: 3.791

7.  Lymphocytes of haemophilia patients treated with clotting factor concentrates display activation-linked cell-surface antigens.

Authors:  U Köller; O Majdic; K Liszka; H Stockinger; I Pabinger-Fasching; K Lechner; W Knapp
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.